Dr Julian Levell is VP of Drug Discovery at Constellation Pharmaceuticals in Boston USA, with responsibility for small molecule research efforts in medicinal chemistry, molecular modelling, structural biology, protein production, DMPK, automation, compound management, biochemistry and biophysics. Julian carried out his PhD research at Cardiff University on organic photochromic molecules, which included co-invention of a series of compounds which were incorporated into Transitions™ lenses. He went on to do postdoctoral research at the University of Florida with Prof Alan Katritzky on the development of novel heterocyclic chemistry methodology. Since then, Julian has worked in biotech and pharma research for over 20 years, spending time in California at Centaur Pharmaceuticals, Pennsylvania and New Jersey at Rhone-Poulenc Rorer / Aventis / Sanofi, and in Boston at the Novartis Institutes for Biomedical Research. During his career, Julian has led teams and projects across multiple disease areas including cardiovascular, diabetes, asthma, neuroscience, and oncology; with 9 programs transitioning through IND. He has also spent time in South Africa to help build drug discovery capabilities at the H3D research center in Cape Town with Prof Kelly Chibale. Julian has over 40 patents and publications, is a member of American Chemical Society, a Fellow of the Royal Society of Chemistry, and is a core member of the NIH National Cancer Institutes (NCI) Experimental Therapeutics (NExT) review committee and Special Emphasis Panel (SEP).